{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:22:04Z","timestamp":1792297324976,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.12.013","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T07:43:52Z","timestamp":1735285432000},"page":"e262-e281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Review of Real-World Experience With Ruxolitinib for Myelofibrosis"],"prefix":"10.1016","volume":"25","author":[{"given":"Haifa Kathrin","family":"Al-Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.12.013_bib0001","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.013_bib0002","doi-asserted-by":"crossref","first-page":"e90299","DOI":"10.1371\/journal.pone.0090299","article-title":"Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN)","volume":"9","author":"Price","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2024.12.013_bib0003","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.12.013_bib0004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2024.12.013_bib0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.12.013_bib0006","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0007","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cancers13050984","article-title":"A broad overview of signaling in Ph-negative classic myeloproliferative neoplasms","volume":"13","author":"Guijarro-Hernandez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.12.013_bib0008","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.12.013_bib0009","year":"2023"},{"key":"10.1016\/j.clml.2024.12.013_bib0010","year":"2024"},{"key":"10.1016\/j.clml.2024.12.013_bib0011","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.12.013_bib0012","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.12.013_bib0013","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2024.12.013_bib0014","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","article-title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","volume":"64","author":"Pemmaraju","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.12.013_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2024.12.013_bib0016","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms, version 2.2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477; 2024 Accessed September 19, 2024."},{"key":"10.1016\/j.clml.2024.12.013_bib0017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0018","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0019","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: international Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.013_bib0020","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.12.013_bib0021","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00277-023-05458-1","article-title":"Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naive to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial","volume":"102","author":"Koschmieder","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0022","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1002\/cam4.5618","article-title":"Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: an Italian MYNERVA project","volume":"12","author":"Coltro","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2024.12.013_bib0023","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood-2018-99-110198","article-title":"Real-world management of myelofibrosis with ruxolitinib: initial analysis of an Italian observational study (ROMEI)","volume":"132","author":"Breccia","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.013_bib0024","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1016\/j.clml.2022.06.008","article-title":"Real-world outcomes of ruxolitinib in patients with myelofibrosis focusing on red blood cell transfusion: a multicenter study from the MPN Working Party of the Korean Society of Hematology","volume":"22","author":"Jung","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.12.013_bib0025","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.3390\/cancers15205027","article-title":"A prognostic model to predict ruxolitinib discontinuation and death in patients with myelofibrosis","volume":"15","author":"Palandri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.12.013_bib0026","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.3390\/cancers15205085","article-title":"Therapeutic results and survival of patients with myelofibrosis treated with ruxolitinib-a real-life longitudinal study","volume":"15","author":"Stoeva","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.12.013_bib0027","article-title":"Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib","volume":"2015","author":"Davis","year":"2015","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0028","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.12.013_bib0029","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","article-title":"Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval","volume":"101","author":"Verstovsek","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0030","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/j.clml.2021.01.025","article-title":"Patterns of care for older patients with myelofibrosis: a population-based study","volume":"21","author":"Meckstroth","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.12.013_bib0031","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2217\/fon-2021-1358","article-title":"Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review","volume":"18","author":"Passamonti","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2024.12.013_bib0032","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.12.013_bib0033","year":"2022"},{"key":"10.1016\/j.clml.2024.12.013_bib0034","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.16729","article-title":"Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis","volume":"191","author":"Barraco","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.12.013_bib0036","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.12.013_bib0037","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0038","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0039","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1002\/cncr.35489","article-title":"Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: the RUX-MF Real-World Study","volume":"130","author":"Palandri","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.12.013_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102859","article-title":"Benefit of early ruxolitinib initiation regardless of fibrosis grade in patients with primary myelofibrosis: a post hoc analysis of the single-arm phase 3b JUMP study","volume":"15","author":"Palandri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.12.013_bib0041","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.013_bib0042","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.013_bib0043","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.15497","article-title":"Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients","volume":"183","author":"Palandri","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0044","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2024.12.013_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0046","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/hematology.2022000340","article-title":"New approaches to tackle cytopenic myelofibrosis","volume":"2022","author":"Reynolds","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2024.12.013_bib0047","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.12.013_bib0048","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clml.2021.10.016","article-title":"Safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts (50 \u2013100 \u00d7 109\/L): final analysis of an open-label phase 2 study","volume":"22","author":"Talpaz","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.12.013_bib0049","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.12.013_bib0050","doi-asserted-by":"crossref","DOI":"10.1159\/000541549","article-title":"Real-world use of ruxolitinib in patients with myelofibrosis and anemia or thrombocytopenia at myelofibrosis diagnosis [Epub ahead of print]","author":"Yu","year":"2024","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0051","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/cncr.34707","article-title":"Early intervention in myelofibrosis and impact on outcomes: a pooled analysis of the COMFORT-I and COMFORT-II studies","volume":"129","author":"Verstovsek","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.12.013_bib0052","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.12.013_bib0053","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000520440","article-title":"Ruxolitinib re-treatment in patients with myelofibrosis: real-world evidence on patient characteristics and outcomes","volume":"145","author":"Gerds","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2024.12.013_bib0054","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/j.clml.2018.06.025","article-title":"Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: a case series","volume":"18","author":"Gerds","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.12.013_bib0055","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.33541","article-title":"Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: frequency, therapeutic effects, and impact on outcome","volume":"127","author":"Palandri","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.12.013_bib0056","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13696998.2023.2224017","article-title":"Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs","volume":"26","author":"Gerds","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.clml.2024.12.013_bib0057","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/oncolo\/oyab058","article-title":"Treatment patterns, health care resource utilization, and cost in patients with myelofibrosis in the United States","volume":"27","author":"Copher","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2024.12.013_bib0058","first-page":"825","article-title":"Cost-effectiveness of ruxolitinib for patients with myelofibrosis: a review of the literature","volume":"5","author":"Karakuleli","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.12.013_bib0059","doi-asserted-by":"crossref","first-page":"A590","DOI":"10.1016\/j.jval.2016.09.1404","article-title":"Cost effectiveness of ruxolitinib versus best available therapy for the treatment of myelofibrosis from public health perspective in Chile","volume":"19","author":"Rojas","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2024.12.013_bib0060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.36469\/9808","article-title":"Cost-effectiveness of ruxolitinib vs best available therapy in the treatment of myelofibrosis in Spain","volume":"5","author":"G\u00f3mez-Casares","year":"2017","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:33:31Z","timestamp":1751398411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024024650"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of Real-World Experience With Ruxolitinib for Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}